Results 51 to 60 of about 16,299 (214)

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya   +9 more
wiley   +1 more source

Phosphodiesterase 9 Inhibition Combined With Valsartan and With Sacubitril/Valsartan in Experimental Ovine Heart Failure

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background LCZ696 (sacubitril/valsartan) antagonizes the renin–angiotensin system while simultaneously augmenting the natriuretic peptides (NPs). Inhibition of phosphodiesterase 9 inhibition (PDE9i), which hydrolyses NP‐generated cGMP may be a more ...
Nicola J. A. Scott   +5 more
doaj   +1 more source

Tripchlorolide attenuates β-amyloid generation by inducing NEP activity in N2a/APP695 cells

open access: yesTranslational Neuroscience, 2021
Alzheimer’s disease (AD) is a neurodegeneration disease. The previous work from our research group demonstrated the neuroprotective effects of tripchlorolide (T4) in AD animal models.
Zeng Yuqi   +4 more
doaj   +1 more source

Effects of BNP and Sacubitrilat/Valsartan on Atrial Functional Reserve and Arrhythmogenesis in Human Myocardium

open access: yesFrontiers in Cardiovascular Medicine, 2022
BackgroundAlthough the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan started a new era in heart failure (HF) treatment, less is known about the tissue-level effects of the drug on the atrial myocardial functional reserve and ...
Uwe Primessnig   +27 more
doaj   +1 more source

N‐terminal pro‐brain natriuretic peptide and cardiorenal outcome in patients with anaemia in chronic kidney disease

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 848-858, April 2025.
Abstract Aims Blood levels of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) may be modified by low renal clearance and anaemia. The aim of this study was to investigate the impact of the blood NT‐proBNP level on cardiovascular and renal outcomes in patients with these two manifestations.
Hiroshi Nishi   +4 more
wiley   +1 more source

Growth differentiation factor‐15 and N‐terminal pro‐BNP in acute heart failure with preserved ejection fraction

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki   +11 more
wiley   +1 more source

Not so Dangerous After All? Venom Composition and Potency of the Pholcid (Daddy Long-Leg) Spider Physocyclus mexicanus

open access: yesFrontiers in Ecology and Evolution, 2019
Pholcid spiders (Araneae: Pholcidae), officially “cellar spiders” but popularly known as “daddy long-legs,” are renown for the potential of deadly toxic venom, even though venom composition and potency has never formally been studied.
Pamela A. Zobel-Thropp   +6 more
doaj   +1 more source

Novel aspect of neprilysin in kidney fibrosis via ACSL4‐mediated ferroptosis of tubular epithelial cells

open access: yesMedComm, 2023
Although inhibition of neprilysin (NEP) might be a therapeutic strategy with the potential to improve the outcome of chronic kidney disease (CKD), the versatile function of NEP with its mechanism remains obscure in kidney fibrosis. In the study, we found
Weijing Lai   +9 more
doaj   +1 more source

Neprilysin inhibition in chronic kidney disease [PDF]

open access: yesNephrology Dialysis Transplantation, 2014
Despite current practice, patients with chronic kidney disease (CKD) are at increased risk of progression to end-stage renal disease and cardiovascular events. Neprilysin inhibition (NEPi) is a new therapeutic strategy with potential to improve outcomes for patients with CKD.
Judge, P   +3 more
openaire   +2 more sources

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy